Description
Created On: 2020-07-15
Record Count: 3
Primary Industries
- Drugs
- Supplements
- Therapeutic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 229588
IPSCIO Record ID: 228654
Licensee, through a wholly owned subsidiary, has purchased an aggregate 1,799,800 shares of the Company’s common stock in conjunction with the Company’s private placement offerings during the years ended December 31, 2012 and 2011. The shares were purchased on the same terms as the other participants acquiring shares in the respective offerings. A director of the licensee company joined the Company’s Board in December 2013.
IPSCIO Record ID: 279364
List of Products:
Glucosamine/Chondroitin
Glucosamine/Chondroitin MSM
Glucosamine Complex
EsterC
Controlled Delivery Technology (CDT)
Patent Rights means all rights to (a) the patents and patent applications identified in this Agreement, (b) any other United States patent or patent application that is owned by Licensor as of the Effective Date and that relates directly or indirectly to any CDT Know-How, any Product, or the design, development, manufacture, testing or use of any Product; and (c) any United States patent or patent application that is filed or acquired by Licensor on or after the Effective Date and that relates directly or indirectly to any CDT Know-How, any CDT Improvements, any Product, or the design, development, manufacture, testing or use of any Product.
US Patent No. 6,337,091-Matrix for controlled delivery of highly soluble pharmaceutical agents
US Patent No. 6,090,411 -Monolithic tablet for controlled drug release
CDT Rights means the Patent Rights, the CDT Know-How, the Other Rights, and the CDT Improvements.
Other Rights means (a) the trademarks identified in this Agreement; (b) any other trademark or service mark that is owned by Licensor as of the Effective Date and that relates directly or indirectly to any Patent Right, any CDT Know-How or any Product; (c) any other Proprietary Right that is owned by Licensor as of the Effective Date (other than the Patent Rights and the CDT Know-How) and that relates directly or indirectly to any Patent Rights, any CDT Know-How, or any Product, (d) any Proprietary Right that is developed or acquired by Licensor on or after the Effective Date (other than any such right that becomes part of the Patent Rights, CDT Know-How, or the CDT Improvements) and that relates directly or indirectly to any Patent Right, any CDT Know-How, any CDT Improvement or any Product; and (e) all goodwill of Licensor associated with the foregoing.
The trademarks identified on this Agreement have been duly registered in the U.S. Patent and Trademark Office. None of the trademarks included in the Other Rights is or has been involved in any opposition or cancellation proceeding, and, to the best of Licensors knowledge, there is no basis for the commencement of any such proceeding. To the best of Licensors knowledge, there are no trademarks owned by third parties that are confusingly similar or dilute any of the trademarks included in the Other Rights.
1. CDT Controlled Delivery Technology trademark with Federal Registration Serial Number 78261152.
2. CDT trademark with Federal Registration Number 2507519.
Licensor's innovative proprietary and patented Controlled Delivery Technology (CDT®) drug delivery technologies enable us to formulate tablets or capsules that release their active agents predictably and programmably over a specified timeframe of up to 24 hours. Our CDT technology platform is designed to reduce the frequency of drug administration, improve the effectiveness of the drug treatment, ensure greater patient compliance with a treatment program, and reduce side effects or increase drug safety. In addition, our amino-acid technology can be incorporated into oral formulations to increase the solubility characteristics of previously non-soluble and sparingly soluble drugs without employing costly micro-milling and coated particle technologies.